ANKE BIO(300009)2022-04-27 16:00Financial Performance - The company's revenue for Q1 2022 was ¥533,355,253.62, representing a 10.01% increase compared to ¥484,825,921.75 in the same period last year[2] - Net profit attributable to shareholders was ¥172,897,830.23, a 37.67% increase from ¥125,584,242.74 year-on-year[2] - Basic earnings per share increased to ¥0.1055, up 37.55% from ¥0.0767 in the same quarter last year[2] - Operating profit for Q1 2022 reached CNY 204,584,893.60, up 38.9% from CNY 147,173,591.27 in Q1 2021[17] - Net profit attributable to shareholders of the parent company was CNY 172,897,830.23, representing a 37.7% increase from CNY 125,584,242.74 in the previous year[18] Cash Flow - The net cash flow from operating activities reached ¥164,433,196.39, showing a significant growth of 96.81% compared to ¥83,549,693.39 in the previous year[2] - The cash inflow from operating activities was CNY 530,877,155.94, an increase of 22.5% compared to CNY 433,181,576.03 in the previous period[20] - The net cash flow from financing activities significantly increased, driven by substantial premium capital increases from external investors in a subsidiary[4] - The net cash flow from financing activities was CNY 15,004,685.21, a significant improvement from CNY 621,720.87 in the same period last year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,914,015,288.42, reflecting a 6.68% increase from ¥3,669,085,976.07 at the end of the previous year[2] - The company's total liabilities amounted to CNY 769,356,188.99, slightly up from CNY 765,521,209.36 year-on-year[15] - The total equity attributable to shareholders of the parent company increased to CNY 3,011,621,986.72 from CNY 2,786,596,726.38, reflecting a growth of 8.1%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 92,450, with the top 10 shareholders holding a combined 36.92% of shares[6] - Song Lihua, the largest shareholder, holds 26.52% of shares, amounting to 434,578,710 shares, with 325,934,032 shares under lock-up[6] - The total number of restricted shares at the beginning of the period was 478,340,656, with 11,773,080 shares released during the period, leaving 466,567,577 shares still restricted[8] - The total number of shares held by the top 10 unrestricted shareholders is 292,000,000 shares, indicating a concentration of ownership[6] Investments and Capital - The company invested RMB 20 million in Shanghai Lanwei Medical Technology Co., Ltd., acquiring a 10% equity stake after the capital increase[9] - The registered capital of the associate company, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., increased from RMB 5.331299 million to RMB 6.184307 million through a capital increase[9] - The company has implemented a stock incentive plan, with a total of 10,654,872 shares released from lock-up on April 1, 2022[8] Research and Development - Research and development expenses for Q1 2022 were CNY 28,996,807.93, a decrease of 11.6% compared to CNY 32,684,673.43 in Q1 2021[17] Regulatory Approvals - The company received approval for a new production line for injectable human growth hormone, significantly increasing its production capacity[10] - The company received a notice of approval for "Amoxicillin Granules" after passing the consistency evaluation of generic drug quality and efficacy[10] Future Plans - The company continues to explore strategic partnerships and investments to enhance its market position and financial performance[9] - The company plans to expand its market presence and invest in new product development to drive future growth[19]